# Zeus Capital: The new age of live-biotherapeutics

- Link: https://www.directorstalkinterviews.com/zeus-capital-new-age-live-biotherapeutics/412725078
- Published: 2017-03-07T14:44:02+00:00
- Author: Giles Arbor

The new age of live-biotherapeutics is the topic of conversation when **Dr Gary 
Waanders, Healthcare Research Director at Zeus Capital** talks to DirectorsTalk.
Gary explains what is driving the interest in this field, the key themes for how
the Live Biotherapeutics Products will work and which companies should we be keeping
an eye on.

 

The awareness of the microbiome and its relationship to human health and disease
has grown in recent years and now attracts much interest from the global pharmaceutical
and biotechnology industry. The human microbiome is comprised of over 100 trillion
microbes which live in a number of different niches on or in the body, but mostly
in the gut. The realisation that these microbes are more than mere ‘passengers’ 
has come about as alterations in the numeric and functional diversity of the microbial
community have been characterised in far greater detail than ever before. Driven
by technology innovations the growing depth of microbiome knowledge has enabled 
the dissection of associations between specific microbial communities and certain
disease states. In this context, the potential to exploit the microbiome to treat
or prevent the development of diseases is now being more fully explored by scientists
and clinicians in both academia and industry. Strategies to therapeutically exploit
the gut microbiome include standard small-molecule drug approaches, selective dietary
supplements and bacteria themselves as therapeutic agents, so called live biotherapeutic
products.

**[⌊Gut Microbiome (DDDD)⌉⌊Gut Microbiome (DDDD)⌉[Global interest in the microbiome**–
the microbiome has been the subject of intense interest by both academia and the
pharmaceutical industry in recent years. This is evidenced by the rapidly growing
number of scientific publications in the field from 247 papers in 2005 to over 5,000
papers in 2015, and almost 400 clinical studies in the USA. Further recognition 
of the clinical potential of the field has come in the form of government sponsored
initiatives such as the Human Microbiome Project launched in 2008 for which the 
US National Institutes of Health (NIH) invested $115m in 2012. This NIH backing 
raised the institutional and scientific credibility of the field and triggered greater
academic and industry efforts to recruit the best scientific talent and technology
development. Significant licensing and co-development deals have followed to secure
access and rights to the technologies and products of innovators and developers.

**Commercial opportunities** – the microbiome could have an impact on diverse diseases
ranging from local conditions of the gut (e.g. Crohn’s disease, ulcerative colitis)
to systemic diseases including autoimmune and neurological disorders (e.g. multiple
sclerosis, Parkinson’s disease), cancer and respiratory ailments (e.g. asthma, COPD).
These therapeutic areas are highly valued as pharmaceutical markets with many products
reaching blockbuster sales levels. Targeting the functions of the gut microbiome
represents a new strategy for therapeutic intervention and drug development. Indeed,
efforts to develop microbiome-targeted drugs include everything from dietary factors
and drugs to enhance or limit certain microbial activity to administering specific
live bacteria themselves as the active therapeutic agents (live biotherapeutic products
or LBPs). LBPs are attractive as product candidates because their derivation from
commensal bacteria enables a shortening of development timelines as health regulators
believe they are safe.

Also in this report:
 4D Pharma Plc (LON:DDDD) Assembly Biosciences Inc (NASDAQ:
ASMB) Evelo Biosciences Oxthera.AB Seres Therapeutics Inc (NASDAQ:MCRB) Synlogic
Vedanta Biosciences

You can download the full report that [Dr Waanders published here](https://www.directorstalkinterviews.com/wp-content/uploads/2017/03/Microbiome-07032017.pdf).

Share on:
